anti-GUCY2C CAR T-cell therapy (Liminatus Pharma)

N/A

Report date: 2025/01/26 19:00:30

Base Information

Drug Nameanti-GUCY2C CAR T-cell therapy (Liminatus Pharma)
Drug Alias NameGCC-Targeted CAR-T cell therapy (Thomas Jefferson University/Liminatus Pharma)anti-GUCY2C CAR T-cell therapy (Thomas Jefferson University)anti-guanylate cyclase 2C CAR T-cell therapy (Thomas Jefferson University)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionHeat-stable enterotoxin receptor modulators
TargetsHeat-stable enterotoxin receptor
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesLiminatus Pharma LLC
Inactive CompaniesThomas Jefferson University
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A